Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Wednesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reissued a neutral rating and set a $1.00 price target on shares of Cytosorbents in a research report on Friday, March 15th.

Cytosorbents Trading Up 1.2 %

NASDAQ:CTSO opened at $0.82 on Wednesday. Cytosorbents has a 1-year low of $0.78 and a 1-year high of $4.29. The business’s 50-day moving average price is $0.93 and its two-hundred day moving average price is $1.16. The company has a current ratio of 1.77, a quick ratio of 1.51 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $44.48 million, a price-to-earnings ratio of -1.28 and a beta of 0.58.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. The company had revenue of $8.67 million during the quarter, compared to the consensus estimate of $9.29 million. On average, equities analysts expect that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Trading of Cytosorbents

A number of hedge funds have recently made changes to their positions in the business. Chicago Partners Investment Group LLC lifted its position in shares of Cytosorbents by 84.0% in the third quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock valued at $67,000 after buying an additional 16,598 shares during the last quarter. Key Client Fiduciary Advisors LLC lifted its holdings in Cytosorbents by 188.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after purchasing an additional 22,557 shares during the last quarter. Raymond James & Associates acquired a new stake in Cytosorbents during the 4th quarter worth approximately $56,000. Sargent Investment Group LLC lifted its holdings in Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after purchasing an additional 51,699 shares during the last quarter. Finally, Skylands Capital LLC lifted its holdings in Cytosorbents by 5.4% during the 3rd quarter. Skylands Capital LLC now owns 2,944,670 shares of the medical research company’s stock worth $5,536,000 after purchasing an additional 151,200 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.